SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Venrock Adviser, LLC

CIK 0001615982 · 7 BRYANT PARK, 23RD FLOOR, NEW YORK, NY, 10018 · 650-475-3734

Reported Value
$1.5B
Q4 2023
Positions
36
Filings on Record
28
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Venrock Adviser, LLC reported $1.5B in U.S.-listed holdings across 36 positions for Q4 2023.

Its largest position, Rayzebio, represents 17.2% of the portfolio.

Compared with Q3 2023, the fund opened 8 new positions and exited 9.

Portfolio Metrics

Turnover
+14.6%
vs prior filed quarter
Top-10 Concentration
+68.3%
share of reported value
Largest Position
+17.2%
Rayzebio
New / Exited
8 / 9
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’20: $369MQ1 ’20Q2 ’20: $418MQ3 ’20: $511MQ4 ’20: $680MQ1 ’21: $922MQ1 ’21Q2 ’21: $824MQ3 ’21: $779MQ4 ’21: $732MQ1 ’22: $617MQ1 ’22Q2 ’22: $554MQ3 ’22: $681MQ4 ’22: $623MQ1 ’23: $512MQ1 ’23Q2 ’23: $625MQ3 ’23: $950MQ4 ’23: $1.5BQ1 ’24: $2.1BQ1 ’24Q2 ’24: $1.6BQ3 ’24: $1.9BQ4 ’24: $1.5BQ1 ’25: $1.2BQ1 ’25Q2 ’25: $1.3BQ3 ’25: $1.8BQ4 ’25: $2.0BQ1 ’26: $2.7BQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 64.4%Other: 34.9%ADR: 0.7%
  • Common Stock · 64.4% · $939M
  • Other · 34.9% · $509M
  • ADR · 0.7% · $11M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SYRESPYRE THERAPEUTICS INCNEW+2.37M2.37M+$51M$51M
OCULOCULAR THERAPEUTIX INCNEW+7.78M7.78M+$35M$35M
AMBRX BIOPHARMA INCNEW+2.07M2.07M+$29M$29M
ARVNARVINAS INCNEW+627.8K627.8K+$26M$26M
CATBUSDASTRIA THERAPEUTICS INCNEW+3.23M3.23M+$25M$25M
ABVXABIVAX SANEW+998.6K998.6K+$11M$11M
PRAXPRAXIS PRECISION MEDICINES INEW+353.6K353.6K+$8M$8M
EYPTEYEPOINT PHARMACEUTICALS INCNEW+250.0K250.0K+$6M$6M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

36 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RAYZEBIO INCCOM17.19%$251M4.03M
2APGEAPOGEE THERAPEUTICS INChistory →COM16.28%$237M8.49M
3PHARVARIS N VCOM6.53%$95M3.40M
4VRDNVIRIDIAN THERAPEUTICS INChistory →COM5.80%$85M3.88M
5FDMT4D MOLECULAR THERAPEUTICS INhistory →COM4.76%$69M3.42M
6MERUS N VCOM4.05%$59M2.15M
7CABACABALETTA BIO INChistory →COM3.99%$58M2.56M
8SYRESPYRE THERAPEUTICS INChistory →COM NEW3.50%$51M2.37M
94XC1KALVISTA PHARMACEUTICALS INChistory →COM3.44%$50M4.09M
10ELVNENLIVEN THERAPEUTICS INChistory →COM2.80%$41M2.95M
11OCULOCULAR THERAPEUTIX INChistory →COM2.38%$35M7.78M
12HILLEVAX INCCOM2.28%$33M2.08M
13AMBRX BIOPHARMA INCCOM2.02%$29M2.07M
14430TERNS PHARMACEUTICALS INChistory →COM2.00%$29M4.50M
15DYNDYNE THERAPEUTICS INChistory →COM1.98%$29M2.17M
16COGTCOGENT BIOSCIENCES INChistory →COM1.89%$28M4.68M
17CELCCELCUITY INChistory →COM1.88%$27M1.89M
18MERSANA THERAPEUTICS INCCOM1.80%$26M11.33M
19ARVNARVINAS INChistory →COM1.77%$26M627.8K
20CATBUSDASTRIA THERAPEUTICS INChistory →COM1.70%$25M3.23M
21RYTMRHYTHM PHARMACEUTICALS INChistory →COM1.56%$23M496.0K
22ORICORIC PHARMACEUTICALS INChistory →COM1.53%$22M2.43M
23APLTAPPLIED THERAPEUTICS INChistory →COM1.44%$21M6.25M
24TSHATAYSHA GENE THERAPIES INChistory →COM SHS1.26%$18M10.41M
25YB4PSAVARA INChistory →COM1.13%$16M3.50M
26LYRA THERAPEUTICS INCCOM0.93%$13M2.58M
27ABVXABIVAX SAhistory →SPONSORED ADS0.73%$11M998.6K
28DNTHDIANTHUS THERAPEUTICS INCCOM0.66%$10M927.7K
29PRAXPRAXIS PRECISION MEDICINES ICOM NEW0.54%$8M353.6K
30GH RESEARCH PLCORDINARY SHARES0.52%$8M1.32M
31ACELYRIN INCCOM0.48%$7M937.1K
32EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.40%$6M250.0K
33TRVITREVI THERAPEUTICS INCCOM0.31%$5M3.42M
34ADVMCHFADVERUM BIOTECHNOLOGIES INCCOM0.27%$4M5.15M
35MISTMILESTONE PHARMACEUTICALS INCOM0.11%$2M925.0K
36OLMAOLEMA PHARMACEUTICALS INCCOM0.07%$1M77.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.7B33May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B27Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.8B33Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.3B31Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.2B37May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.5B37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.9B38Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.6B35Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.1B38May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.5B36Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$950M37Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$625M30Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$512M25May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$623M29Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$681M32Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$554M28Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$617M27May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$732M26Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$779M26Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$824M29Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$922M28May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$680M25Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$511M22Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$418M16Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$369M16May 15, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.